NASDAQ:NGEN NervGen Pharma Q1 2026 Earnings Report $2.32 -0.01 (-0.43%) As of 09/3/2026 04:00 PM Eastern ProfileEarnings HistoryForecast NervGen Pharma EPS ResultsActual EPS-$0.09Consensus EPS -$0.07Beat/MissMissed by -$0.02One Year Ago EPSN/ANervGen Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANervGen Pharma Announcement DetailsQuarterQ1 2026Date5/15/2026TimeAfter Market ClosesConference Call DateMonday, May 18, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) NervGen Pharma Earnings HeadlinesBrokerages Set NervGen Pharma (NASDAQ:NGEN) PT at $14.00August 30, 2026 | americanbankingnews.comNervGen Pharma Corp.: NervGen Reports Second Quarter 2026 Financial Results and Provides Business UpdatesAugust 13, 2026 | finanznachrichten.deMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets. | Paradigm Press (Ad)NervGen Pharma Posts Larger Q2 2026 Loss but Strengthens Cash PositionAugust 13, 2026 | tipranks.comNervGen Reports Second Quarter 2026 Financial Results and Provides Business UpdatesAugust 13, 2026 | globenewswire.comNervGen Pharma Corp. : NGENJuly 13, 2026 | 247wallst.comSee More NervGen Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NervGen Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NervGen Pharma and other key companies, straight to your email. Email Address About NervGen PharmaNervGen Pharma (NASDAQ:NGEN) Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments. The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings. NervGen’s development activities center on progressing NVG-291 and related research through clinical trials to assess safety, tolerability and potential to improve functional outcomes for patients with neurological damage. NervGen is publicly traded on the NASDAQ under the ticker NGEN and operates as a research-driven biopharmaceutical organization. The company conducts clinical development activities and research collaborations to support its programs and to advance regulatory development pathways for its therapeutics. As a clinical-stage company, NervGen’s prospects are tied to the progress and results of its clinical trials and development partnerships. Its work is representative of the broader effort in biotechnology to develop novel regenerative treatments for conditions with significant unmet medical need in neurology. Investors and stakeholders typically follow clinical milestones and regulatory updates when evaluating the company’s progress. View NervGen Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth StoryPalo Alto Networks Is Expensive—But Its Growth Is AcceleratingMongoDB’s Spending Fears Collide With a Much Stronger Growth StoryGitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse TestWith the RSI at a Record Low, Is It Time to Go Bargain Hunting on Burlington?Enova’s Earnings Surge Meets a Valuation Test Upcoming Earnings Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
